WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
PR & Media
Strategic support to drive communications programmes and build visibility
Marketing
Effectively promote products and services to generate leads
Design & Branding
Elevate company image with bespoke design services for websites and corporate materials
Investor Relations
Strengthen relationships with investors through targeted outreach

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
BioForward 2026
-
Drug Discovery Innovators & Investors Event Series: Innovation to Investment – Driving Growth in Early-stage Drug Discovery
-
ELRIG Drug Discovery 2026
-
Innovate Cambridge Summit 2026
FairJourney Bio Announces Scientific Program and Leadership for The Antibody Series 2026
Annual event brings together international experts in antibody discovery and development, taking place September 16–18, 2026, in Évora, Portugal Porto, Portugal, 21 July 2026: FairJourney Bio (“FJBio”), a global antibody [...]
DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences
Brings decentralized, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market Paris, France, 16 June 2026: DNA Script, the programmable biology company developing next-generation enzymatic DNA synthesis [...]
EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy
ClearPoint Neuro’s system enables precise delivery to the seizure focus, ensuring best possible efficacy and safety of EpilepsyGTx’s investigational gene therapy Partnership will support first-in-human Phase 1/2a clinical trials of [...]





















